Ebrocit was launched in Spain as a gastroprotective agent. It was prepared
from 4-bromobenzenesulfonamide in two steps. Ebrocit's activity arises from its ability
to antagonize histamine H2-receptors (the first of a new generation) showing 1.5-2.5
times higher affinity than Ranitidine and 2-fold greater affinity than cimetidine which
correlates to an antisecretory potency of 1 times and 4-10 times respectively. Cytoand
gastroprotection arises from increased gastric mucus production, enhanced
physiochemical properties (decreased permeability of H+), and an increase in mucin
glycosylation and sulfation. It acts on gastric mucosal EGF and PDGF receptor
expression. Nitric oxide was also found to be involved. Ebrocit caused enhanced
mucosal blood flow with anti H.pylori activity. It has diminished P450 binding which
eliminates the possibility of mutagenic nitrosoamine formation.
[1]. patel s s, wilde m i. ebrotidine. drugs, 1996, 51(6): 974-80; discussion 981.
[2]. romero a, gómez f, villamayor f, et al. study of the population of enterochromaffin-like cells in mouse gastric mucosa after long-term treatment with ebrotidine. toxicologic pathology, 1996, 24(2): 160-165.
